MARKET

RIGL

RIGL

Rigel Pharmaceuticals Inc
NASDAQ
28.07
-0.80
-2.77%
Closed 16:10 03/09 EDT
OPEN
28.29
PREV CLOSE
28.87
HIGH
29.26
LOW
27.72
VOLUME
561.35K
TURNOVER
0
52 WEEK HIGH
52.24
52 WEEK LOW
15.50
MARKET CAP
518.54M
P/E (TTM)
1.441
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RIGL last week (0302-0306)?
Weekly Report · 23h ago
Assessing Rigel Pharmaceuticals (RIGL) Valuation After Strong Q4 And Full Year 2025 Earnings Results
Simply Wall St · 2d ago
Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty
TipRanks · 5d ago
Rigel Pharmaceuticals (RIGL) EPS Spike On Non Cash Gains Challenges Bullish Narratives
Simply Wall St · 5d ago
Rigel Pharma slides as falling contract revenue to drive contraction
Seeking Alpha · 5d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 5d ago
Nasdaq Surges Over 1%; ISM Services PMI Tops Views
Benzinga · 5d ago
Cantor Fitzgerald Remains a Hold on Rigel (RIGL)
TipRanks · 5d ago
More
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

Webull offers Rigel Pharmaceuticals Inc stock information, including NASDAQ: RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.